E

    Enliven Therapeutics Inc. (ELVN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $57.89
    +0.03 (+0.05%)

    Market Cap: $4.24B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(17/26)
    Avg Surprise
    -3.85%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.45
    Range$-0.52 - $-0.38
    5 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$-0.48-7.1%
    60d ago$-0.45-1.0%
    30d ago$-0.43+3.5%
    7d ago$-0.48-6.4%
    Current$-0.45
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.63
    Range$-0.84 - $-0.17
    5 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.63---
    Sep 26EST
    		-$-0.45---
    Jun 26
    Reported Aug 5
    		$-0.49$-0.38-28.95%Miss+0.0%
    Mar 26
    Reported May 7
    		$-0.38$-0.41+7.32%Beat+33.3%
    Dec 25
    Reported Mar 3
    		$-0.48$-0.38-27.05%Miss-4.3%
    Sep 25
    Reported Nov 12
    		$-0.32$-0.46+30.43%Beat+33.3%
    Jun 25
    Reported Aug 13
    		$-0.49$-0.42-16.67%Miss-19.5%
    Mar 25
    Reported May 14
    		$-0.57$-0.50-14.00%Miss-5.6%
    Dec 24
    Reported Mar 13
    		$-0.46$-0.52+11.11%Beat+2.1%
    Sep 24
    Reported Nov 13
    		$-0.48$-0.50+4.00%Beat+5.9%
    Jun 24
    Reported Aug 13
    		$-0.41$-0.56+26.79%Beat+0.0%
    Mar 24
    Reported May 14
    		$-0.54$-0.57+5.26%Beat+32.5%
    Dec 23
    Reported Mar 14
    		$-0.47$-0.54+12.96%Beat-138.8%
    Sep 23
    Reported Nov 9
    		$-0.51$-0.47-8.51%Miss+29.2%
    Jun 23
    Reported Aug 10
    		$-0.41$-0.40-2.50%Miss+76.7%
    Mar 23
    Reported May 11
    		$-0.80$-0.52-53.85%Miss+64.3%
    Dec 22
    Reported Feb 10
    		$1.21$-0.79+253.94%Beat+157.1%
    Sep 22
    Reported Oct 25
    		$-0.72$-1.00+28.00%Beat+67.3%
    Jun 22
    Reported Aug 3
    		$-1.76$-2.05+14.15%Beat+40.5%
    Mar 22
    Reported May 6
    		$-2.24$-2.31+3.03%Beat+3.4%
    Dec 21
    Reported Mar 15
    		$-2.12$-3.00+29.33%Beat+5.4%
    Sep 21
    Reported Nov 9
    		$-2.20$-3.38+34.91%Beat+23.6%
    Jun 21
    Reported Aug 6
    		$-2.96$-3.20+7.50%Beat-25.4%
    Mar 21
    Reported May 11
    		$-2.32$-3.34+30.54%Beat+86.5%
    Dec 20
    Reported Mar 5
    		$-2.24$-3.35+33.13%Beat-229.4%
    Sep 20
    Reported Nov 5
    		$-2.88$-3.21+10.28%Beat-800.0%
    Jun 20
    Reported Aug 14
    		$-2.36$-2.25-4.89%Miss-
    Mar 20
    Reported May 7
    		$-17.24$-2.94-486.39%Miss-
    Dec 19
    Reported Mar 11
    		$-0.68$0.00N/AMiss-
    Sep 19
    Reported Oct 8
    		$-0.32$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-34.66EV/EBITDA-6.28x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-15.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio64.07xQuick Ratio64.07x
    Trading Statistics
    Beta0.24Avg Volume1.05M
    52-Week High$62.3252-Week Low$14.79

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$59.75
    SMA 20$59.58
    SMA 50$54.78
    SMA 200$36.88
    EMA 10$59.31
    EMA 20$58.58
    EMA 50$54.57
    EMA 200$40.70

    MACD

    Line: 1.41Signal: 1.94Hist: -0.52

    ADX

    ADX: 33.6+DI: 19.9-DI: 22.1

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down4.0
    PSAR$62.00

    Bollinger Bands

    Upper Band$61.80
    Lower Band$57.35
    %B Position747%(Upper)
    Band Width0.12

    RSI (14-Day)

    Neutral
    50.8

    Momentum Oscillators

    Stoch %K40.4
    Stoch %D58.4
    Williams %R-72.5
    ROC (10d)-2.8%
    Momentum-1.65
    CCI (20d)-142.2
    MFI (14d)50.2

    Volatility Measures

    ATR (14d)$2.38(4.1%)
    StdDev (20d)1.11
    Hist Vol31.2%(Moderate)

    Volume Flow

    VWAP$57.67
    OBV64.3M
    AD Line18.8M
    CMF (20d)0.116

    Volume Metrics

    Avg Vol (20d)963.1K
    Vol Ratio1.0x
    VWMA (20d)$59.77

    Pivot Points

    R3$63.57
    R2$62.37
    R1$60.12
    Pivot Point$58.92
    S1$56.67
    S2$55.47
    S3$53.22

    Advanced Oscillators

    TSI21.55
    Ultimate Osc45.2
    KST106.81

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$316,000$0$0$0$440,000$0
    Cost of Revenue$0$0$46,000$0$0$0$158,000$0$0$0$77,000$0
    Gross Profit$0$0$-46,000$0$0$0$158,000$0$0$0$363,000$0
    Operating Expenses$37.21M$27.82M$34.28M$25.10M$28.58M$31.69M$26.90M$27.07M$24.60M$25.99M$22.73M$24.25M
    R&D$29.00M$20.69M$21.25M$18.23M$21.49M$24.89M$20.72M$21.26M$18.83M$19.97M$17.91M$19.61M
    SG&A$8.21M$7.14M$13.04M$6.87M$7.09M$6.80M$6.17M$5.81M$5.78M$6.02M$4.82M$4.64M
    Operating Income$-37,209,000$-27,823,000$-34,285,000$-25,096,000$-28,584,000$-31,693,000$-26,896,000$-27,068,000$-24,603,000$-25,987,000$-22,729,000$-24,248,000
    Interest Income$4.73M$4.20M$4.62M$4.95M$3.25M$3.20M$3.72M$3.84M$4.09M$3.25M$3.37M$3.49M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-32,485,000$-23,627,000$-29,667,000$-20,148,000$-25,335,000$-28,544,000$-24,053,000$-23,156,000$-19,718,000$-22,738,000$-19,370,000$-20,769,000
    Income Tax Expense$0$0$0$0$0$0$0$0$232,000$0$0$0
    Net Income$-32,485,000$-23,627,000$-29,667,000$-20,148,000$-25,335,000$-28,544,000$-23,180,000$-23,156,000$-19,950,000$-22,738,000$-19,370,000$-20,769,000
    EBITDA$-36,699,000$-27,543,000$-34,184,000$-25,344,000$-28,432,000$-31,711,000$-26,713,000$-26,203,000$-24,329,000$-26,570,000$-24,448,000$-26,167,000
    EBIT$-37,217,000$-27,823,000$-34,285,000$-25,096,000$-28,586,000$-31,740,000$-27,769,000$-26,995,000$-23,804,000$-25,988,000$-22,738,000$-24,261,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ELVN

    News

    Discipline and Rules-Based Execution in ELVN Response

    This article provides an AI-generated analysis of Enliven Therapeutics Inc. (NASDAQ: ELVN), indicating a neutral near and mid-term outlook with a potentially positive long-term bias. It outlines various institutional trading strategies, including long, breakout, and short positions, based on different risk profiles and time horizons. The analysis also highlights specific support and resistance levels, emphasizing risk-reward ratios for potential trades.

    Stock Traders Daily•8/31/26•
    Somewhat-Bearish

    Handelsbanken Fonder AB Buys New Shares in Enliven Therapeutics, Inc. $ELVN

    Handelsbanken Fonder AB acquired 17,300 shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) valued at approximately $878,000 during the second quarter. Institutional investors and hedge funds now collectively own 95.08% of the company's stock, while insider transactions show sales totaling $11.3 million over the past 90 days. Despite a recent earnings miss, analysts maintain a "Moderate Buy" rating with an average price target of $75.00 for ELVN.

    MarketBeat•8/20/26•
    Neutral

    Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

    William Blair initiated coverage on Enliven Therapeutics (NASDAQ: ELVN) with an Outperform rating, highlighting the potential of its lead drug candidate, ELVN-001, to transform chronic myeloid leukemia (CML) treatment. ELVN-001 has shown positive Phase 1 data, demonstrating significant major molecular response rates, and the company has a cash runway into 2030. Analysts believe ELVN-001 could disrupt the CML market due to its differentiated profile and effectiveness against resistance mutations to current market leaders.

    Sahm•8/20/26•
    Bullish

    Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

    Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares of ELVN stock on August 17th for over $352,000, reducing his direct ownership by 13.07%. This transaction was part of a pre-arranged trading plan, following similar sales in July and June. Despite the insider selling, analyst sentiment remains a "Moderate Buy" with an average price target of $75.00, though the company recently missed EPS expectations.

    MarketBeat•8/19/26•
    Neutral

    Enliven (NASDAQ: ELVN) CFO sells 6,018 shares in 10b5-1 plan

    Enliven Therapeutics, Inc.'s CFO, Benjamin Hohl, sold a total of 6,018 shares of Common Stock in two open-market transactions on August 17, 2026, under a Rule 10b5-1 trading plan. The sales were executed at weighted average prices around $58-$59 per share. A portion of these securities were restricted stock units (RSUs), contingent on vesting conditions.

    Stock Titan•8/19/26•
    Somewhat-Bearish

    Frequently Asked Questions About ELVN

    Does ELVN pay dividends?
    Enliven Therapeutics Inc. (ELVN) does not currently pay a regular dividend.
    What is ELVN's market cap?
    Enliven Therapeutics Inc. (ELVN) has a market capitalization of $4.24B with a current stock price of $57.89.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In